You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

150 Results
Drug
Other Name(s): Suprefact® , Suprefact Depot® , Suprefact Nasal Spray®
Nov 2024
Drug
Other Name(s): Leukeran®
Nov 2024
Drug
Other Name(s): Busulfex® , Myleran®
Jun 2019
Drug
Other Name(s): Xeloda®
Jul 2024
Drug
Other Name(s): Casodex® (multiple brands available)
Apr 2024
Drug
Other Name(s): Procytox®
Oct 2020
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
ODB - General Benefit
    bicalutamide
May 2019
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
  • buserelin
ODB - General Benefit
  • bicalutamide
Oct 2016
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
  • buserelin
Oct 2016
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Intent: Adjuvant, Palliative
Funding:
ODB - General Benefit
    capecitabine
Jul 2024
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Palliative
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Advanced Gastric, Gastroesophageal, or Esophageal Cancer
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Apr 2023

Pages